OncoCyte (OCX)
(Delayed Data from NSDQ)
$3.24 USD
+0.07 (2.05%)
Updated Jul 23, 2024 03:59 PM ET
After-Market: $3.22 -0.02 (-0.46%) 6:20 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for OncoCyte Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9 | 20 | 37 | 8 | 22 |
Receivables | 0 | 2 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 3 | 1 | 1 | 1 |
Total Current Assets | 11 | 26 | 39 | 9 | 23 |
Net Property & Equipment | 4 | 9 | 6 | 7 | 4 |
Investments & Advances | 0 | 0 | 0 | 13 | 11 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 57 | 62 | 110 | 24 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 75 | 100 | 160 | 55 | 40 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 1 | 2 | 1 |
Accounts Payable | 1 | 1 | 2 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 8 | 10 | 6 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 2 | 0 | 0 | 0 |
Total Current Liabilities | 7 | 12 | 14 | 9 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 2 | 2 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 3 |
Other Non-Current Liabilities | 45 | 51 | 77 | 7 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 54 | 66 | 94 | 22 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 310 | 295 | 253 | 157 | 125 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -290 | -261 | -188 | -124 | -94 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 20 | 34 | 65 | 33 | 31 |
Total Liabilities & Shareholder's Equity | 75 | 100 | 160 | 55 | 40 |
Total Common Equity | 20 | 34 | 65 | 33 | 31 |
Shares Outstanding | 8.20 | 5.90 | 4.60 | 3.40 | 2.60 |
Book Value Per Share | 2.50 | 5.81 | 14.18 | 9.85 | 11.86 |
Fiscal Year End for OncoCyte Corporation falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 6 | 9 | 14 | 18 |
Receivables | NA | 0 | 0 | 2 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 1 | 1 |
Total Current Assets | NA | 7 | 11 | 17 | 21 |
Net Property & Equipment | NA | 4 | 4 | 4 | 6 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 57 | 57 | 57 | 57 |
Deposits & Other Assets | NA | 2 | 2 | 2 | 2 |
Total Assets | NA | 71 | 75 | 82 | 88 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 7 | 6 | 6 | 6 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 8 | 7 | 8 | 8 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 45 | 34 | 34 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 59 | 54 | 44 | 44 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 311 | 310 | 310 | 310 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | -299 | -290 | -272 | -266 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 12 | 20 | 38 | 44 |
Total Liabilities & Shareholder's Equity | NA | 71 | 75 | 82 | 88 |
Total Common Equity | 0 | 12 | 20 | 38 | 44 |
Shares Outstanding | 8.20 | 8.20 | 8.20 | 8.20 | 8.20 |
Book Value Per Share | 0.00 | 1.41 | 2.50 | 4.58 | 5.32 |